BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With Biogen’s Aducanumab approval dramatically overhauling the
  regulatory landscape for neurodegenerative disease\, the beta amyloid re
 vival is in full swing with investment pouring in across multiple neurode
 generative diseases. With this\, biopharma across the globe are racing to
  harness the exhilarating momentum of the past year and turbocharge their
  neurodegenerative disease drug development in 2022 and beyond.\n\nFrom l
 everaging data from clinical samples to catalyze the next generation of t
 herapies against Alzheimer’s and Parkinson’s disease\, learning how to ju
 stify investment in rare neurodegenerative diseases\, through to taking a
  multi-omic approach to target discovery\, the 10th Neurodegenerative Dru
 g Development Summit will siphon critical insights from Biogen\, AbbVie\,
  Roche\, Takeda\, Novartis and more to help you accelerate therapeutic de
 velopment through to approval for NDD patients around the world.\n\nJoin 
 us to witness this neuroscience renaissance head on and meet with the big
 gest neurodegenerative KOL’s across this exceedingly challenging and exci
 ting field\, as we fight to unravel the complexities of neurodegenerative
  drug development. Join 200+ neurodegenerative drug development experts t
 o learn from those revolutionising this space into 2022 and beyond.\n
DTEND:20220330T153000
DTSTAMP:20260512T220337Z
DTSTART:20220328T080000
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, Massachusetts\, 0211
 6\,
SEQUENCE:0
SUMMARY:With Biogen’s Aducanumab approval dramatically overhauling the reg
 ulatory landscape for neurodegenerative disease\, the beta amyloid reviva
 l is in f...
UID:eb5d7263-35bb-44ed-831a-d677441913ea
END:VEVENT
END:VCALENDAR